Sanofi SA is forecasting a 7% to 10% decline in earnings per share this year at constant exchange rates as the expirations of patents on key products continue to weigh on results and provisions are made against inventory write-offs in Brazil. ---Subscribe to MedNous to access this article--- Company News
